Watchlist

Watchlist
AmpliPhi Biosciences Corporation (APHB)
AmpliPhi Biosciences Corporation (APHB)
AmpliPhi Biosciences Provides Corporate and Strategic Update
Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018 Company expects to continue its expanded acc…
AmpliPhi Biosciences to Present at LD Micro 10th Annual Main Event
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Paul C. Grint, M.D., Chief Executive Officer, will present a compa…
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will …
AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q3 2017 Results - Earnings Call Transcript
Ampliphi Biosciences Corp. (APHB) Q3 2017 Results Earnings Conference Call November 14, 2017, 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts David Bautz - Zacks Investment Research Keit…
AmpliPhi Biosciences reports Q3 results
AmpliPhi Biosciences (NYSEMKT: APHB ): Q3 EPS of -$0.09 Revenue of $0.04M (+33.3% Y/Y) Shares +6.1% . Press Release More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights
Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational First…
AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday,…
AmpliPhi Biosciences to Participate in the BIO-Europe 2017 Conference
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Igor P. Bilinsky, Ph.D., Chief Operating Officer, will present a c…
Premarket Gainers as of 9:05 am
SSKN +38% on deal with aesthetic medical market-focused group purchasing organization. More news on: STRATA Skin Sciences, Inc, Spectrum Pharmaceuticals, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more …
AmpliPhi Biosciences to Participate in Two Upcoming Conferences
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will present a company overview at two upcoming investo…
AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced the publication of preclinical data demonstrating the activity of AB-PA…
AmpliPhi Biosciences Corporation (APHB)
AmpliPhi Biosciences Corporation (APHB)